E Stock Profile: Roche Holding AG ADR

Roche Holding (RHHBY), a global pioneer in pharmaceuticals and diagnostics, offers differentiated products in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Headquartered in Basel, Switzerland, Roche operates in over 100 countries and employs 100,000 people worldwide.

Medic, Hospital, Laboratory, Medical, Health, Doctor

Image Source: Pixabay

Market Leader

In 1896, when the industrial revolution was changing the face of Europe, 28-year-old Fritz HoffmannLa Roche launched his company in Basel, Switzerland. Fritz was among the first to recognize that the industrial manufacture of medicines would advance the fight against disease. Known for producing vitamins, the company became the first to mass-produce synthetic vitamin C.

Since then, Roche Holding has grown into one of the world’s leading healthcare companies with products spanning the healthcare spectrum, from early detection and prevention of disease to diagnosis and treatment. Combining strengths and expertise of its two divisions, Pharmaceuticals and Diagnostics, Roche plays an increasingly important role in shaping the future of personalized healthcare to deliver clinically differentiated drugs.

Much of Roche’s leadership in pharmaceuticals stems from its $47 billion Genentech acquisition in 2009. Pharmaceutical division sales, which accounted for nearly 80% of total for three blockbuster drugs that represented more than 30% of 2019 sales. Strong global uptake of new medicines partly compensated for erosion in sales of drugs coming off patent protection. Indeed, medicines launched since 2012 increased 32% in 2020 and now sales. Roche’s pipeline is full with four new drugs authorized for use in 2020 and a record 19 new compounds either enrolled in registrational studies or awaiting regulatory approval.

Diagnostics division sales, which accounted for 20% of total 2020 sales, increased a healthy 14% in constant currency thanks to sales of COVID-related tests, which more than offset the COVID-related decline in routine testing across the portfolio.

1 2
View single page >> |

Disclaimer: Copying, reproduction or quotation is strictly prohibited without written permission. Information presented here was obtained from sources believed to be reliable but accuracy and ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.